Brief: Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing And Amendment To Existing Convertible Note
16/03/2026 12:20
March 16 (Reuters) - Outlook Therapeutics Inc OTLK.O: OUTLOOK THERAPEUTICS ANNOUNCES NEW $18.4 MILLION NON-CONVERTIBLE NOTE FINANCING AND AMENDMENT TO EXISTING CONVERTIBLE NOTE OUTLOOK THERAPEUTICS INC - EXTENDS MATURITY DATE OF EXISTING CONVERTIBLE NOTE TO DECEMBER 31, 2026 OUTLOOK THERAPEUTICS INC - LENDER CONFIRMS EXISTING NOTE IS NOT IN DEFAULT OUTLOOK THERAPEUTICS INC - ENTERS $18.4 MILLION NEW NOTE, EXPECTS $17 MILLION NET PROCEEDS OUTLOOK THERAPEUTICS INC - PROCEEDS FROM NEW NOTE TO PAY DOWN EXISTING NOTE, $10.8 MILLION PRINCIPAL AND INTEREST REMAINING ON EXISTING NOTE Source text: ID:nGNX8lBlF8 Further company coverage: OTLK.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce